Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.00% $2.66
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 125.46 mill |
EPS: | -2.78 |
P/E: | -0.960 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 47.17 mill |
Avg Daily Volume: | 0.369 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.960 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.16x |
Company: PE -0.960 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.569 (-78.60%) $-2.09 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 2.58 - 2.74 ( +/- 3.12%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Krishnamohan Neha | Sell | 1 506 | Common Stock |
2024-03-01 | Meltz Mark A | Sell | 558 | Common Stock |
2024-03-01 | Williams Richard Thomas | Sell | 558 | Common Stock |
2023-12-01 | Williams Richard Thomas | Sell | 541 | Common Stock |
2023-12-01 | Krishnamohan Neha | Sell | 1 459 | Common Stock |
INSIDER POWER |
---|
99.73 |
Last 96 transactions |
Buy: 16 586 943 | Sell: 15 783 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.66 (0.00% ) |
Volume | 0.189 mill |
Avg. Vol. | 0.369 mill |
% of Avg. Vol | 51.19 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.33 | N/A | Active |
---|
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.